Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech develops pelareorep, an investigational systemically delivered immunotherapy for cancer that has been shown to activate innate immune-sensing pathways. Company news centers on pelareorep clinical and translational data, FDA interactions, and study activity across gastrointestinal and other solid tumor indications, including metastatic colorectal cancer, squamous cell anal carcinoma, pancreatic cancer, and breast cancer.
Recurring updates also cover the company's registration-focused development priorities, Fast Track Designation for pelareorep-based treatment in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, scientific meeting presentations, financing arrangements, and its completed change of jurisdiction to Nevada while ONCY common stock continues to trade on Nasdaq.
Oncolytics Biotech (NASDAQ: ONCY) announces its participation in the Canaccord Genuity 41st Annual Growth Conference, scheduled for August 10-12, 2021. Dr. Matt Coffey, CEO, will present on August 12 at 1:30 p.m. EDT. The event includes one-on-one investor meetings, and a live webcast will be available on Oncolytics' Investor Relations page, archived for 90 days. The company develops pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing immune responses. For more information, visit their website.
Oncolytics Biotech (NASDAQ: ONCY) will hold a conference call on August 6, 2021, at 8:00 a.m. ET to discuss the second quarter financial results and corporate updates. The call will be accessible via a toll-free number and will also be available through a webcast for three months. The biotechnology company is focused on developing pelareorep, an immunotherapeutic agent that induces anti-cancer immune responses. This agent is currently in clinical trials for various cancers, including a registration study in metastatic breast cancer.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced it will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 4:30 PM Eastern Daylight Time. Dr. Matt Coffey, President & CEO, will lead the presentation. A live webcast will be available on the company's Investor Relations page and archived for 90 days. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing immune responses. The company is also engaging in one-on-one investor meetings during the conference.
Oncolytics Biotech (NASDAQ: ONCY) announced a promising clinical proof-of-concept for its pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The phase 2 trial, featuring pembrolizumab (KEYTRUDA), showed a 42% disease control rate among patients who had progressed after first-line treatment. The results will be presented at the ASCO Annual Meeting in June 2021. Key findings highlight enhanced T cell activation and well-tolerated treatment. Oncolytics plans to further develop this therapy in collaboration with Roche through the GOBLET study.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 pm ET. Dr. Matt Coffey, President & CEO, will present, with a live webcast available on the company’s Investor Relations page. The conference runs from May 18-20, 2021, featuring one-on-one investor meetings. Oncolytics is developing pelareorep, an immuno-oncolytic virus aimed at treating various cancers, including in combination with checkpoint inhibitors. For more details, visit Oncolytics' website.
Oncolytics Biotech announced the voting results from its Annual General Meeting held on May 7, 2021, with 41.41% of shares represented. All seven nominated directors were elected, receiving significant support: Deborah M. Brown (82.43%), Matthew C. Coffey (79.86%), and others exceeding 79% approval. Shareholders also approved resolutions relating to the number of directors and auditor appointments. Oncolytics continues to develop pelareorep for cancer treatment, highlighting ongoing clinical trials and strategic plans for a phase 3 registration study in metastatic breast cancer.
Oncolytics Biotech (NASDAQ: ONCY) reported solid clinical progress and financial results for Q1 2021. Key highlights include the successful achievement of primary endpoints in the AWARE-1 trial and strong preclinical data supporting pelareorep's synergy with various immunotherapeutic agents, including CAR T therapies. With over $50 million in cash, the company expects a cash runway through Q4 2022. The Phase 2 BRACELET-1 trial remains on track for full enrollment in Q4 2021, supporting the potential for enhanced breast cancer treatments.
Oncolytics Biotech (NASDAQ: ONCY) announces its upcoming 2021 Annual General Meeting, scheduled for May 7, 2021, at 12:00 p.m. ET. The meeting will be held virtually to ensure the safety of employees and shareholders. Shareholders are encouraged to vote by proxy before the May 5 deadline. Following the meeting, Oncolytics will provide a corporate update and discuss its first quarter 2021 financial results. The event will be accessible online. For detailed instructions on attending and voting, participants can refer to the company's Management Information Circular.
Oncolytics Biotech announced the acceptance of an abstract for its pancreatic adenocarcinoma trial at the 2021 ASCO Annual Meeting, scheduled virtually from June 4-8, 2021. The abstract, titled Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma, will be presented as an electronic poster.
Publication of the abstract will occur on May 19, 2021, while the poster will be available on June 4, 2021. Oncolytics continues to develop pelareorep, targeting various cancers and preparing for a phase 3 trial in metastatic breast cancer.
Oncolytics Biotech announced successful results from the AWARE-1 breast cancer study, achieving its primary endpoint. The study demonstrated that pelareorep, combined with the PD-L1 inhibitor atezolizumab, significantly enhances anti-cancer immune responses in HR+/HER2- patients. Key findings include a 60% increase in CelTIL score in cohort 2, indicating improved tumor immune activity. Management highlights the results as validation of their clinical strategy, paving the way for future registrational studies. The data underscores pelareorep's potential to boost checkpoint inhibitor efficacy in breast cancer treatments.